Nektar Therapeutics
NKTRNektar Therapeutics (NKTR) is a biotechnology company focused on developing innovative immuno-oncology, pain, and inflammatory treatments. It leverages its proprietary drug discovery platform to create therapies that stimulate the body's immune system to fight diseases, particularly cancer. The company collaborates with other pharmaceutical firms and seeks to bring novel therapies to market through its research and development efforts.
Company News
ADARx Pharmaceuticals announced the appointment of Dr. Mary Tagliaferri to its Board of Directors, highlighting her extensive experience in clinical development and drug strategy across biotechnology organizations.
Biotech company Nektar Therapeutics reported Q2 earnings with lower revenue compared to last year, but received positive market reaction and FDA Fast Track designation for an investigational drug targeting alopecia areata.
Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.
Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. See why NKTR stock is a Hold.
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin. Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monda...
